Supplementary information

N-Methyl-D-Aspartate (NMDA) and cannabinoid CB₂ receptors form functional complexes in cells of the nervous system. Insights into the therapeutic potential of neuronal and microglial NMDA receptors.

Running title. Cannabinoid-NMDA receptor interactions

Rafael Rivas-Santisteban^{1,2}, Alejandro Lillo^{3,4}, Jaume Lillo^{1,2}, Joan-Biel Rebassa⁴, Joan S. Contestí⁴, Carlos A. Saura^{1,3}, Rafael Franco^{1,2,5*}, Gemma Navarro^{1,3,4*}

Affiliations:

¹Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Valderrebollo, 5, 28031 Madrid, Spain; carlos.saura@uab.cat

² Departament de Bioquímica i Biomedicina Molecular, Universitat de Barcelona, 08028 Barcelona, Spain

³ Institut de Neurociències, Department de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain


⁴ Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain

⁵ School of Chemistry. University of Barcelona, Barcelona, Spain.

*Corresponding authors:

Rafael Franco (<u>rfranco123@gmail.com</u>; rfranco@ub.edu) School of Biology. Universitat de Barcelona. Diagonal 643. Prevosti Building. Barcelona 08028. Spain Tel +34 934021208

Gemma Navarro (<u>g.navarro@ub.edu</u>) School of Pharmacy. Universitat de Barcelona Joan XXIII, 29-31 Barcelona 08028. Spain Tel +34 934034500



Supplementary figure 1. Signaling in HEK-293T cells expressing NMDA and GHSR1a receptors. HEK-293T cells transfected with the cDNAs for two protomers of the NMDA receptor: GluN1 (1 μ g) and GluN2B (0.75 μ g) and/or with the cDNA for the GHS-R1a (1 μ g), were treated with selective agonists (15 μ M NMDA for NMDAR and/or 100 nM Ghrelin for GHS-R1a). When indicated cells were pretreated with selective receptor antagonists (1 μ M MK-801 for NMDA or 1 μ M YIL-781 for GHS-R1a). Panels A-C: Intracellular cAMP levels were determined by TR-FRET as described in Methods. As G_i coupling was assessed, decreases in cAMP levels were determined in cells previously treated with 0.5 μ M forskolin (15 min). Values are the mean ± S.E.M. of 3 independent experiments performed in triplicates. ANOVA Summary: Panel A; F: 90.94, p<0.001, Panel B; F: 52.09, p<0.001 and Panel C; F: 49,64, p<0.001.